PTJ
NAMS icon

Paul Tudor Jones’s NewAmsterdam Pharma NAMS Stock Holding History

Paul Tudor Jones’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.69M Buy
+79,460
New +$2.62M ﹤0.01% 1739
2025
Q1 		– Sell
-52,208
Closed -$1.34M – 3447
2024
Q4 		$1.34M Buy
+52,208
New +$1.11M 0.01% 1527

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Paul Tudor Jones's NAMS Position: Q2 2026 in Review

Paul Tudor Jones opened a new position in NewAmsterdam Pharma (NAMS) in Q2 2026: 79,460 shares worth $2.69M. The stake represents ﹤0.01% of the portfolio and ranks #1739 among its holdings. This is a return to the name: Paul Tudor Jones previously reported a position in NAMS as recently as Q4 2024.

Paul Tudor Jones first reported a position in NAMS in Q4 2024 and has held it in 2 quarters since. 194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • Paul Tudor Jones held 79,460 shares of NewAmsterdam Pharma worth $2.69M as of Q2 2026.
  • NewAmsterdam Pharma was a new Paul Tudor Jones position in Q2 2026.
  • NewAmsterdam Pharma made up ﹤0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #1739 holding.
  • Paul Tudor Jones first reported a position in NewAmsterdam Pharma in Q4 2024 and has held it in 2 quarters since.
  • 194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.